Introduction
The last decade has seen the emergence of a new paradigm in medicine known as evidence based medicine (EBM) [1, 2] . This process places greater emphasis on evidence obtained from randomised clinical trials or meta-analysis of randomised clinical trials [3] , when making treatment recommendations for individual patient care. In addition, regulatory authorities increasingly require evidence from randomised trials before new therapies, or new indications for existing therapies are approved [4] . This paper broadly reviews the issues concerning patient and physician participation in randomised clinical trials. Searches were undertaken of several electronic databases (Medline, Embase, Psychlit and Cinhail) using the following subject headings: clinical trials, randomised clinical trials, attitudes of health personnel, patient participation, informed consent, ethics, decision-making, patient education and physician-patient relations.
Ethics of clinical trials
In accord with utilitarian moral theory [5] , society permits experimentation with human subjects because of the benefits that the society, as well as the experimental subject, may gain from the new medical knowledge [6] . However, individual rights based theory asserts that the rights of individuals cannot be subsumed by the interests of society as a whole. Thus the fundamental ethical issue surrounding clinical trials reflects a conflict between the need to safeguard individual patients versus the obligation to society to facilitate research [7] .
Randomised clinical trials appear ethically justified when there is a genuine state of uncertainty or equipoise about the comparative merits of two treatments for a particular condition [7] . It has been argued that clinical trials should address questions where there is collective uncertainty within the expert medical community [8] , However, an individual clinician's decision to recruit patients to a randomised trial is more likely to be influenced by their individual uncertainty than collective uncertainty.
Public perception of clinical trials has strong overtones of medical experimentation and of subjects being used as guinea pigs. Such images make a pronounced distinction between clinical practice and clinical research. These distinctions are reinforced by differing standards of consent for treatment as part of a clinical trial and standard treatment outside of the setting of a clinical trial [9] . However, clinical practice may involve as great a degree of experimentation as a clinical trial [5] .
In order to safeguard the interests of clinical trial participants, there is an ethical obligation that trials be of sufficient quality to have a favourable impact on society in the future [10] . The evaluation of the ethical foundation of the design and implementation of clinical trials needs to assess not only the degree of uncertainty surrounding the trial question, but also the anticipated benefits from the trial, the assumed risks by the participants and the alternative treatment options available for the patient [5] . However, few cancer patients receive treatment as part of a formalised clinical trial [11, 12] . Within institutions involved in clinical research, less than 50% of eligible patients are enrolled onto clinical trials [13] [14] [15] . As a consequence, the answers to current research questions are delayed and at times the generalisability of the results produced from these trials is called into question [16] . Low accrual to clinical trials is likely to reflect a multiplicity of issues, including concerns of both the doctor and patient and the complexity of many clinical trial protocols (Table 1) .
Are there benefits for patients participating in clinical trials? The treatments offered to control groups in a randomised clinical trial ought to represent the current best standard treatment, while those allocated to the new treatment are receiving a treatment hypothesised to be similarly effective or better [17] . Therefore it has been argued that well designed randomised trials offer patients the optimum treatment approach [9] .
A number of authors have suggested that outcomes for patients receiving treatment in a clinical trial are improved beyond standard expectations [18] [19] [20] . Additionally doctors who participate in clinical trials may more readily apply the results of clinical trials into clinical practice, suggesting the possibility that there may be benefits for patients who receive treatment at a hospital or institution involved in clinical trials research [21] [22] [23] . Several authors have also suggested that there may be psychological benefits for patients participating in clinical trials [24, 25] .
Doctors' attitudes to randomised clinical trials
The decision by the doctor not to offer a patient the option of participation in a clinical trial is a major reason for poor accrual to clinical trials [14] . Clinical trials are perceived by many doctors to conflict with the individual decision-making and clinical judgement skills which they learnt in medical school [26] . Many doctors have difficulty acknowledging uncertainty regarding therapeutic benefit, or discussing treatment choices with patients, including participation in clinical trials [27, 28] . Taylor, surveying principal investigators in a trial comparing segmental versus total mastectomy, found that the most common reasons for not accruing patients
Trial factors
Poorly designed or complex trial protocols Presence of a no treatment arm Large difference between treatment arms, e.g., surgery versus radiotherapy Toxic therapy being tested Standard therapy arm not considered standard therapy Eligibility requirements too narrow Irrelevant or unimportant trial question were concerns regarding the doctor-patient relationship, difficulties with informed consent and dislike of open discussions about uncertainty [29] . These issues appear to reflect doctors' personal discomfort with the conduct of randomised clinical trials. Other researchers have found that logistical difficulties and concerns about the treatments offered on a clinical trial were major reasons for not entering patients onto clinical trials [30] . A survey of Australian cancer specialists treating breast cancer found that only half were participating in breast cancer clinical trials [31] . Lack of resources including limited access to data management, lack of time and a feeling that clinical trial participation was not worth the effort was a major reason for not entering patients onto clinical trials. Many respondents also questioned the relevance of the study questions and the choice of standard therapies.
Therefore efforts to increase doctors' participation in randomised clinical trials need to overcome both a reluctance of some doctors to recommend/propose patients enter onto clinical trials and the logistical problems (time and resources) which make participation difficult.
Patients' attitudes about clinical trials
There appears to be general community acceptance of the need to include patients in medical research [32, 33] . However, far fewer patients would consider participating personally in a randomised clinical trial [33] .
Reasons for participating in clinical trials
It has been argued that the only reason patients would participate in clinical trials is that they choose to be altruistic [34] . Cassileth found that benefiting others and advancing medical knowledge were highly rated as reasons for participating in clinical trials [32] . Other authors have also found that contributing to scientific knowledge is rated highly by patients [35, 36] .
However, many patients choose to participate in clinical trials in the hope of receiving better care or treatment [37] [38] [39] . A systematic review of published literature examining patients' motivation to participate in clinical trials concludes that self interest is a more common reason for participating than altruism [40] .
A number of demographic characteristics have also been reported to be associated with willingness to participate in randomised clinical trials. Males, patients who are older, less well educated, or from lower socioeconomic backgrounds appear more willing to participate in clinical trials [41] [42] [43] . Additionally, patients who trust their doctor appear more likely to participate in clinical trials if asked [24] . These patient groups may also prefer to receive less information about their illness and are more likely to leave treatment decision-making to their doctor [44, 45] . Access to free health care has also been reported as a motivation to participate in clinical trials. These issues all raise concerns about the possibility of subtle coercion of such patients to join randomised trials.
Reasons for not participating in randomised clinical trials
Despite favourable attitudes towards research in general, many people decide not to participate in a clinical trial themselves. Random allocation of treatment is a major reason why patients choose not to join randomised clinical trials [33, 46] . Many patients appear to have a poor understanding of the rationale for randomisation as a method of treatment allocation and express reservations or feelings that it is unfair [46, 47] .
Patients may also be reluctant to participate in randomised clinical trials because of a desire to be actively involved in clinical decision-making. Several studies have demonstrated that patients commonly decline to participate because of a preference for either the doctor or themselves to make the decision about which treatment they will receive [35, 45] .
A variety of other factors are reported in the literature to be influential in patients' decision to participate in randomised clinical trials. Many patients express objection to being an experimental subject, or report feeling 
Elements of informed consent
• The person must be provided with sufficient information about treatment, outcomes of treatment including risks and benefits and any alternative treatment approaches • The information must be given in a form that is comprehensible by the person • The person must be competent to give consent • The consent must be given voluntarily without undue coercion • Information about the person will remain confidential • The doctor must make themselves available to answer questions the person may have
Additional elements of informed consent for clinical trials
• The nature and purpose of the study must be explained including the method of treatment allocation • An explanation of any additional tests, procedures or extra risks incurred in the trial compared with treatment received off the trial must be provided • The details of any financial compensation in the event of a research related injury must be explained • The person should understand that participation is voluntary and they may withdraw from the trial at any time without compromising their care • Written information sheets about the trial must be provided and the person give written consent like a guinea pig [48] . Distrust of the medical profession and a lack of knowledge of what is required of trial participants is also a barrier to recruitment [49] . Additionally patients may express concerns about the specific treatments offered on a clinical trial. Trials in which there are large differences in the treatments offered, particularly in regard to toxicity or the possibility of receiving a placebo, often experience greater difficulties with recruitment [50] [51] [52] .
Views of clinical trial participants
Surveys of patients who participated in randomised clinical trials of cardiovascular treatments show that they are generally satisfied with their experience [42, 53] . Most state they would volunteer for the trial if they had to do it over again and that they would be happy to recommend the trial, or one similar, to a friend. Only a minority of people perceived there were disadvantages and that these were largely practical issues or nuisance problems. Whilst similar data are not available for randomised trials in oncology, a survey of patients participating in phase 1-11 cancer clinical trials found that they were generally happy with their experience on trial [54] .
Informed consent for clinical trials
The goal of informed consent is to provide sufficient information to patients about the treatment, its benefits and side effects and the alternative treatments in order for the patient to make an autonomous decision [55, 56] .
There are a number of essential elements of informed consent (Table 2) . However, if informed consent is sought for participation in clinical trials then there are additional elements of informed consent including the need to explain the nature and purpose of the study, any additional tests, procedures or risks involved in the study compared with standard treatment, the voluntary nature of the research and the provision of written information [57, 58] . There is evidence however, that the goals of informed consent for clinical trials are not always achieved [59] . Several studies demonstrate that patients receiving either standard treatment or treatment as part of a clinical trial recall only a small proportion of information provided to them [60] [61] [62] . Olver surveyed oncology patients about to receive chemotherapy in the context of a clinical trial [62] . Nearly half the patients could not name any of the drugs which they were about to receive and less than half could remember at least half of the side effects described on the consent form.
Poor recall and understanding of information may also arise as a consequence of doctors' views about informed consent for clinical trials. Taylor surveyed 170 physicians involved in clinical research [63] . The majority of doctors felt that informed consent requirements for clinical trials were an intrusion into the doctorpatient relationship and many doctors remain unconvinced that full disclosure is in the patients' best interests, even when patients express a desire to know all the facts. Williams and Zwitter surveyed investigators from multicentre randomised clinical trials published in the European Journal of Cancer over a two-year period [64] . Only 62% of respondents routinely told all of their patients that treatment would be selected at random and only 58% gave patients information about all of the treatment options.
Cancer patients considering entry onto clinical trials are generally provided with written information. However, the complexity of material presented in consent forms may impede patient understanding and recall of information. Grossman et al. examined the readability of consent forms from oncology protocols at Johns Hopkins Oncology Centre over a two-year period [65] . The reading age or readability reflects the average number of years of education required to read and comprehend the material. The mean reading age of consent forms was 14.1 years suggesting that consent forms for clinical trials were too complex for many patients to read and understand. Davis et al. randomised subjects to receive a standard Southwest Oncology Group (SWOG) consent form (readability 12th grade, equivalent to 12 years of schooling) or a simplified form using headings text and diagrams (readability 7th grade, equivalent to 7 years of schooling) [66] . Subjects preferred the simplified form (62% vs. 38%) and more subjects would be discouraged to participate by the more complex form (12% vs. 2%).
There would appear to be a paradox between the need to provide greater amounts of information about clinical trials when seeking informed consent and the apparent preference of patients to receive more simplified information. These studies would suggest that strategies to improve informed consent procedures for clinical trials need to look at ways to improve patient recall of information, as well as ways to increase both the amount of information provided to patients and patients'comprehension of that information.
Can we improve patient understanding about clinical trials
There are several studies which suggest that patient understanding about clinical trials can be improved through the provision of greater amounts of information (Table 3 ) [67] [68] [69] . Simes et al. randomised patients eligible for entry into randomised trials of chemotherapy to either full or individualised disclosure of information [67] . Patients in the full disclosure group had significantly greater knowledge about their illness and treatment and also about the research plan. They demonstrated higher anxiety levels immediately post consultation, although these differences were no longer apparent after four weeks. Patients in the full disclosure group were a little more likely to decline trial participation (18% vs. 7%), however, this difference was not significant.
Aaronson et al. evaluated a strategy of providing additional information to patients considering entry into phase II or III trials [68] . Patients were randomised to the standard consent interview, or the standard interview followed by a telephone call several days later from a clinical trials nurse to further discuss the information provided in the consent interview. Significantly more patients randomised to the nurse intervention were aware that they had been asked to undergo treatment in the context of a clinical trial. They were more knowledgeable about the broad aspects of the clinical trial, randomisation procedures, the voluntary nature of the trial and their right to withdraw, plus the availability of alternative treatments. There were no differences in anxiety levels observed between the groups. As in the Simes study, patients in the intervention group were slightly more likely to decline participation (24% vs. 13%).
Davis et al. randomised patients considering entry into phase III clinical trials to receive either standard information about clinical trials or standard information plus a National Cancer Initiative booklet explaining clinical trials [69] . Patients who received the booklet were more knowledgeable overall about clinical trials, but there were no differences observed in participation rates.
Llewellyn-Thomas et al. examined different ways of presenting information about clinical trials [70] . They randomised patients undergoing radiotherapy to receive information about a hypothetical clinical trial by either audiotape or interactive computer program. Patients randomised to receive information via the interactive computer were more likely to agree to join the hypothetical trial (62% vs. 42%), however this difference was of borderline statistical significance. Among patients who viewed the interactive computer program, those who declined to participate had higher mean understanding scores.
The results of all these studies suggest that patient education can improve understanding about clinical trials. The provision of more information to patients considering entry into clinical trials preserves autonomy, improves recall and understanding of information, but may impede recruitment to clinical trials. The results raise important ethical considerations about the informed consent process for clinical trials.
Future directions
Continued efforts to improve recruitment to clinical trials are justified given the increasing importance of randomised clinical trials in advancing the evidence base on which to make future treatment recommendations. There are a number of areas that warrant further research. Baum has suggested that there is a need to raise community awareness about the need for and importance of randomised clinical trials [71, 72] . He comments on the ethical difficulties in discussing uncertainty about treatment approaches and seeking informed consent for clinical trials from patients soon after a diagnosis of a serious and potentially life threatening illness such as cancer.
The timing of such education should also the be the focus of future research. Cupples found that among patients receiving preoperative education about coronary artery bypass graft surgery, that patients who received education one week prior to surgery had greater knowledge, more positive mood, higher physiologic recovery scores and less anxiety than those receiving preadmission education [73] .
Finally there is a need for additional research examining doctor-patient communication about clinical trial information. Poor recall and understanding of information by patients may reflect inadequate or poorly presented information by doctors. Future research should address the question whether communication skills training for doctors will improve patient recall and understanding of information and what impact this will have on patients' willingness to participate in randomised clinical trials.
